Skip to main content
Clinical Trials/NCT07255560
NCT07255560
Completed
Not Applicable

Clinical Evaluation of the Cosmetic Efficacy of the Product DMAE Oleate Aimed at Increasing Skin Firmness and Reducing Fine Lines and Wrinkles in Human Volunteers.

Bionos Biotech S.L.1 site in 1 country30 target enrollmentStarted: September 9, 2025Last updated:
InterventionsTopical DMAE Oleate

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Bionos Biotech S.L.
Enrollment
30
Locations
1
Primary Endpoint
Quantification of the change in facial fine lines and wrinkles (crow's-feet) - area, depth, and volume - from baseline to post-treatment visits using VISIA-CR®.

Overview

Brief Summary

This single-arm, cosmetic study will evaluate the efficacy of topical DMAE Oleate on facial skin firmness and lines/wrinkles in healthy adults. Thirty volunteers (40-55 years) will apply DMAE Oleate at night for 12 weeks (week 1: Monday/Wednesday/Friday/Sunday; weeks 2 to 12: nightly, one pump dose). Efficacy will be assessed at baseline, week 4, week 8, and week 12. The primary goals are to determine changes in fine lines/wrinkles at the crow's-feet region and biomechanical properties of the face skin. Wrinkle area, depth, and volume will be quantified by standardized VISIA-CR® image analysis, while firmness, elasticity, and fatigue will be measured with a Cutometer®. Participants will also complete a self-assessment questionnaire at each time point. Measurements are performed under identical conditions at all visits to enable within-subject comparisons from baseline.

Detailed Description

Skin aging reflects intrinsic and extrinsic processes that reduce collagen/elastin, diminish hyaluronic acid, and compromise firmness and elasticity, leading to fine lines and wrinkles. In this cosmetic study, investigators will assess the efficacy of topical DMAE Oleate on facial skin by quantifying changes in fine lines/wrinkles and biomechanical parameters of firmness, elasticity, and fatigue in healthy adult volunteers.

Thirty healthy volunteers aged 40-55 years with visible fine lines/wrinkles and signs of laxity/sagging will be enrolled at Bionos Biotech S.L. (Valencia, Spain) following informed consent and eligibility confirmation. Participants will receive DMAE Oleate in individual containers and will apply one pump topically once daily at night according to a fixed regimen: Week 1 on Monday, Wednesday, Friday, and Sunday; Weeks 2-12 nightly. Product handling and use will follow written instructions (apply to clean, dry facial skin; avoid the eye area; allow normal absorption before any other routine), and containers will be collected/verified at visits to support compliance documentation. All procedures and data processing will take place at Bionos Biotech facilities under standardized site conditions.

Assessments will be performed at baseline (D0), week 4 (D28), week 8 (D56), and week 12 (D84), in the same order at each visit to enable within-subject comparisons: (1) VISIA-CR® imaging of the crow's-feet region to quantify wrinkle area, depth, and volume; (2) Cutometer® measurements on facial skin to determine firmness, elasticity, and fatigue; and (3) completion of a self-assessment questionnaire. Participants will be reminded to maintain normal diet and hygiene, to refrain from initiating new/interfering cosmetics or oral supplements, to avoid excessive sun exposure and self-tanning/tanning salons, and to forgo intense or invasive cosmetic procedures for the study duration. The investigational product has undergone the required safety patch test prior to volunteer use; adverse events will be collected at each visit and managed according to site procedures. Volunteers must maintain normal diet and hygiene, refrain from starting new/interfering cosmetics or oral supplements, avoid excessive sun exposure and self-tanning/tanning salons, and forgo intense/invasive cosmetic treatments; contraception methods should remain unchanged from 6 weeks prior through study end. Key exclusions include sensitive skin; eczema/rosacea; pregnancy, breastfeeding, or planned pregnancy; and known allergy/sensitivity to product components.

The primary analysis will compare within-subject changes from baseline to post-treatment time points using paired t-tests or Wilcoxon signed-rank tests (two-sided α=0.05). A sample of 30 participants is expected, based on prior center experience, to detect ≈5-10% differences with 80% power, acknowledging that this is the first evaluation of this product.

Ethical conduct follows the Declaration of Helsinki, ICH guidelines, and local committee approvals; informed consent was obtained before any procedure. Data are coded and handled under Spanish data-protection law.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
40 Years to 55 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Volunteers with visible signs of fine lines and wrinkles.
  • Volunteers with visible signs of skin laxity/sagging.
  • Informed of the purpose and the protocol of the study and signed a written informed-consent form.
  • Additional criteria to be included by the client.

Exclusion Criteria

  • Volunteers with sensitive skin.
  • Pre-existing skin conditions: Eczema, Rosacea.
  • Pregnancy/breastfeeding/planning pregnancy.
  • Known allergy/sensitivity to any component of the product.
  • Agree to avoid excessive sun exposure/self-tanning product/avoid tanning salons/solariums.
  • No lasers/tretinoin/procedures/facial hair removal/facials 2 weeks prior or during the study.
  • Additional criteria to be included by the client.
  • Any condition judged by the investigator to be unsuitable for participation in the study.

Arms & Interventions

DMAE Oleate

Experimental

This group will be provided with the product DMAE Oleate.

Intervention: Topical DMAE Oleate (Other)

Outcomes

Primary Outcomes

Quantification of the change in facial fine lines and wrinkles (crow's-feet) - area, depth, and volume - from baseline to post-treatment visits using VISIA-CR®.

Time Frame: Baseline (before product application) and after 4, 8, and 12 weeks of application.

Thirty healthy volunteers (40-55 years) will apply topical DMAE Oleate for 12 weeks (week 1: Monday/Wednesday/Friday/Sunday at night; weeks 2 to 12: nightly, one pump). Standardized image capture with VISIA-CR® will be performed on the crow's-feet region at baseline (D0) and at 4 (D28), 8 (D56), and 12 weeks (D84) after application to compute wrinkle area, depth, and volume. All procedures are conducted at Bionos Biotech S.L. facilities under a fixed schedule; product is supplied in individual containers, one-pump dose, stored cool and dry. A safety patch test has been completed prior to volunteer use.

Quantification of the skin firmness, elasticity, and fatigue from baseline to post-treatment visits using Cutometer®.

Time Frame: Baseline (before product application) and after 4, 8, and 12 weeks of application.

Thirty healthy volunteers (40-55 years) will apply topical DMAE Oleate for 12 weeks (week 1: Monday/Wednesday/Friday/Sunday at night; weeks 2 to 12: nightly, one pump). Cutometer® measurements will be performed on facial skin to determine firmness, elasticity, and fatigue at baseline (D0) and at 4 (D28), 8 (D56), and 12 weeks (D84) after application. All procedures are conducted at Bionos Biotech S.L. facilities under a fixed schedule; product is supplied in individual containers, one-pump dose, stored cool and dry. A safety patch test has been completed prior to volunteer use.

Completion of a self-assessment questionnaire.

Time Frame: Baseline (before product application) and after 4, 8, and 12 weeks of application.

Thirty healthy volunteers (40-55 years) will apply topical DMAE Oleate for 12 weeks (week 1: Monday/Wednesday/Friday/Sunday at night; weeks 2 to 12: nightly, one pump). Participants will complete a self-assessment questionnaire at baseline (D0) and at 4 (D28), 8 (D56), and 12 weeks (D84) after application to provide a subjective evaluation of the treatment. All procedures are conducted at Bionos Biotech S.L. facilities under a fixed schedule; product is supplied in individual containers, one-pump dose, stored cool and dry. A safety patch test has been completed prior to volunteer use.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Bionos Biotech S.L.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials